Latest Conference Articles

Secukinumab affects levels of inflammatory biomarkers, and monitoring levels can help investigators understand how patients are responding to treatment.

In addition, the length of hospital admissions were greater in patients with hidradenitis suppurativa-associated cutaneous squamous cell carcinoma compared to other admissions.

The biosimilarity was evident between SB17 (Samsung Bioepis), ustekinumab (Stelara; Janssen Immunology), and those switching from ustekinumab to SB17.

The CORe initiative is aimed at promoting inclusivity, reducing startup time for clinical trials, and facilitating data sharing to address recruitment and retention challenges in cancer research at community oncology sites.

Although regulation takes time, real safety concerns for patients in the rapid development of AI technology in health care are present today.

Although cancer death rates have decreased in the United States overall, they continue to rise in rural Appalachia, engendering a malaise of fatalism in the region.

Will Shapiro, vice president of Data Science at Flatiron Health, provides context into the terminology and history of these models.

The ACCC 50th Annual Meeting & Cancer Center Business Summit is taking place in Washington, DC from February 28 to March 1.

Compared to embolization alone, the systemic treatment combination nearly doubled progression-free survival among patients with unresectable liver cancer.

Radioligands may be able to deliver radiation to advanced tumor cells anywhere in the body.

No established standard of care currently exists after spread to the lymph nodes.

Compared to TACE alone, durvalumab plus TACE and bevacizumab reduced the risk of disease progression or death by 23%; however, further research is needed to assess OS.

The combination resulted in numerically longer OS compared with an NSAI alone.

The MRD-guided treatment approach has a significant advantage over chemotherapy.

It can also help identify patients who would benefit from disease-specific therapies.

Data support the quadruplet regimen as a new standard of care for transplant-eligible patients.

Public Health Pharmacist discussed wearable technology and AI assisted technology that was displayed at the 2024 Consumer Electronics Show

Significant study results could inform clinical practice strategies.

Presentations detail clinical trial results and focus on drugs in the pipeline.

2023 was an impactful year for the field of oncology pharmacy.

In the Augment-101 phase 2 study, 63% of patients experienced overall response rate with revumenib.

This therapeutic could work for diseases of the B cell receptor signaling transduction pathway that do not respond well to single-agent BTK inhibitor.

According to the findings, the use of venetoclax, as well as other new therapies, improved overall survival from 28.6% to 45.3% in non-Hispanic Black patients with AML.

Expert discusses positive, real-world findings from a claims-based study looking at this therapeutic.

Investigators will evaluate prophylactic tocilizumab prior to treatment with teclistamab.

Douglas Warner, MD, chief medical officer at eFFECTOR, provides a comprehensive overview of zotatifin and its current status in a Phase 1/2 dose escalation and expansion study, with a focus on ER+/HER2- breast cancer.

Heather McArthur, MD, clinical director of breast oncology at UT Southwestern Medical Center, discusses the toxicities associated with antibody-drug conjugates (ADCs) used in breast cancer treatment at the 2023 San Antonio Breast Cancer Symposium.

There is progress being made regarding research on immunotherapies and the mutation, which adversely affects a higher number of patients in this population.